2020
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Skiles J, Yu L, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood 2020, 136: 33. DOI: 10.1182/blood-2020-142696.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAbsolute neutrophil countVaso-occlusive episodesG-CSF administrationNeutrophil recoveryG-CSFSCD patientsCell diseaseDay 100Unrelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationVaso-occlusive pain crisesHemoglobin S levelPrimary graft rejectionShort-course methotrexateAcute chest syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorTranscranial Doppler velocitiesDifferent donor sourcesColony-stimulating factorSafety/toxicity
2019
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances 2019, 3: 1441-1449. PMID: 31053571, PMCID: PMC6517657, DOI: 10.1182/bloodadvances.2018030171.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlemtuzumabBone Marrow CellsChildChild, PreschoolDisease-Free SurvivalFemaleFetal BloodGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaProportional Hazards ModelsRecurrenceSurvival RateThyroglobulinTransplantation ConditioningWhole-Body IrradiationConceptsRelapse-free survivalPediatric patientsGrade IIIBM groupAcute leukemiaHigh riskAlternative donor hematopoietic cell transplantationTotal body irradiation-based conditioningMultivariate analysisDonor hematopoietic cell transplantationFree relapse-free survivalCox proportional hazards modelAnti-thymocyte globulinHematopoietic cell transplantationIrradiation-based conditioningAcute lymphoblastic leukemiaProportional hazards modelUmbilical cord bloodBM recipientsGraft variablesGVHD prophylaxisUCB groupHost diseaseMycophenolate mofetilClinical characteristics